Pacira BioSciences, Inc.
PCRX
$27.00
-$0.14-0.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 700.97M | 694.96M | 690.31M | 681.75M | 674.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 700.97M | 694.96M | 690.31M | 681.75M | 674.98M |
| Cost of Revenue | 233.59M | 236.96M | 239.58M | 243.32M | 243.82M |
| Gross Profit | 467.37M | 457.99M | 450.73M | 438.44M | 431.15M |
| SG&A Expenses | 294.10M | 280.29M | 273.90M | 270.62M | 269.44M |
| Depreciation & Amortization | 57.29M | 57.29M | 57.29M | 57.29M | 57.29M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 603.39M | 592.95M | 589.18M | 588.33M | 587.66M |
| Operating Income | 97.57M | 102.01M | 101.13M | 93.42M | 87.32M |
| Income Before Tax | -63.11M | -54.91M | 100.55M | 101.82M | 61.70M |
| Income Tax Expenses | 36.45M | 35.82M | 36.95M | 31.35M | 19.75M |
| Earnings from Continuing Operations | -99.56 | -90.73 | 63.59 | 70.47 | 41.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.56M | -90.73M | 63.59M | 70.47M | 41.96M |
| EBIT | 97.57M | 102.01M | 101.13M | 93.42M | 87.32M |
| EBITDA | 176.36M | 178.03M | 175.34M | 167.82M | 162.90M |
| EPS Basic | -2.16 | -1.97 | 1.37 | 1.52 | 0.90 |
| Normalized Basic EPS | 1.36 | 1.41 | 1.37 | 1.23 | 1.06 |
| EPS Diluted | -2.20 | -1.99 | 1.34 | 1.47 | 0.85 |
| Normalized Diluted EPS | 1.27 | 1.30 | 1.23 | 1.10 | 0.94 |
| Average Basic Shares Outstanding | 184.98M | 185.24M | 185.53M | 185.44M | 184.89M |
| Average Diluted Shares Outstanding | 197.90M | 200.93M | 206.86M | 208.38M | 202.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |